Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Treasury Shares (2016 - 2025)

Karyopharm Therapeutics' Treasury Shares history spans 13 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 55.59% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 55.59%, while the annual FY2025 figure was $1.3 million, 55.59% up from the prior year.
  • Treasury Shares reached $1.3 million in Q4 2025 per KPTI's latest filing, up from $850738.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $7.7 million in Q4 2023 to a low of $850738.0 in Q4 2024.
  • Average Treasury Shares over 5 years is $3.1 million, with a median of $2.3 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: soared 125.3% in 2023, then plummeted 88.9% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $2.3 million in 2021, then skyrocketed by 47.91% to $3.4 million in 2022, then surged by 125.3% to $7.7 million in 2023, then tumbled by 88.9% to $850738.0 in 2024, then surged by 55.59% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Treasury Shares are $1.3 million (Q4 2025), $850738.0 (Q4 2024), and $7.7 million (Q4 2023).